Escitalopram oxalate - Generic Drug Details

What are the generic sources for escitalopram oxalate and what is the scope of patent protection?

Escitalopram oxalate is the generic ingredient in three branded drugs marketed by Almatica, Rising, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Chartwell Molecular, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Sun Pharma Canada, Abbvie, Accord Hlthcare, Aiping Pharm Inc, Ascent Pharms Inc, Chartwell Rx, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Cadista, Novitium Pharma, Prinston Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Lifesciences, and is included in twenty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for escitalopram oxalate. Forty-five suppliers are listed for this compound. There are six tentative approvals for this compound.

Summary for escitalopram oxalate

US Patents:	0
Tradenames:	3
Applicants:	23
NDAs:	27
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	45
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	25
Drug Prices:	Drug price trends for escitalopram oxalate
Drug Sales Revenues:	Drug sales revenues for escitalopram oxalate
What excipients (inactive ingredients) are in escitalopram oxalate?	escitalopram oxalate excipients list
DailyMed Link:	escitalopram oxalate at DailyMed

See drug prices for escitalopram oxalate

See drug sales revenues for escitalopram oxalate

Recent Clinical Trials for escitalopram oxalate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The First Hospital of Hebei Medical University	NA
West China Hospital	NA
The First Affiliated Hospital, Zhejiang University	NA

See all escitalopram oxalate clinical trials

Generic filers with tentative approvals for ESCITALOPRAM OXALATE

Applicant	Application No.	Strength	Dosage Form
		20MG	TABLET; ORAL
		10MG	TABLET; ORAL
		5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for escitalopram oxalate

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for escitalopram oxalate

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ESCITALOPRAM OXALATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXAPRO	Capsules	escitalopram oxalate	5 mg	021323	1	2005-08-17
LEXAPRO	Capsules	escitalopram oxalate	10 mg and 20 mg	021323	1	2005-03-30

US Patents and Regulatory Information for escitalopram oxalate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	AB	RX	Yes	No
Zydus Lifesciences	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	077734-002	Sep 11, 2012	AB	RX	No	No
Accord Hlthcare	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	202389-001	Sep 11, 2012	AB	RX	No	No
Torrent Pharms Ltd	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	090939-002	Sep 11, 2012	AB	RX	No	No

Expired US Patents for escitalopram oxalate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002
Abbvie	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002
Abbvie	LEXAPRO	escitalopram oxalate	SOLUTION;ORAL	021365-001	Nov 27, 2002

Market Dynamics and Financial Trajectory for Escitalopram Oxalate

Last updated: July 27, 2025

Introduction

Escitalopram oxalate, marketed under the brand name Lexapro among others, is a selective serotonin reuptake inhibitor (SSRI) primarily prescribed for major depressive disorder and generalized anxiety disorder. Since its FDA approval in 2002, escitalopram has maintained a significant position in the psychiatric medication market. Its market dynamics and financial trajectory are influenced by multiple factors, including clinical efficacy, patent lifecycle, competitive landscape, regulatory environment, and evolving healthcare trends.

---

Market Overview

The global antidepressant market, estimated to reach USD 18.5 billion by 2026[1], forms the primary landscape for escitalopram. As a core component of this sector, escitalopram's share hinges on its clinical profile, tolerability, and market acceptance. The drug's high binding specificity, favorable side effect profile relative to earlier SSRIs, and extensive clinical validation underpin its enduring demand.

---

Market Drivers

1. Increasing Prevalence of Mental Health Disorders
The World Health Organization estimates over 264 million individuals worldwide suffer from depression, with anxiety disorders affecting over 284 million[2]. Escitalopram's efficacy in treating these conditions sustains its demand.

2. Expanding Prescription Adoption
Physicians favor escitalopram due to its tolerability, which reduces discontinuation rates. Its once-daily dosing and quick onset of action encourage prescriber preference, bolstering market penetration.

3. Growing Awareness and Reduced Stigma
Global mental health initiatives increase diagnosis and treatment initiation, expanding the patient base for SSRIs like escitalopram.

4. Patent Expiry and Generic Competition
The original patent for Lexapro expired in the U.S. in 2012, leading to rapid entry of generic formulations, significantly reducing costs and expanding access[3].

---

Market Challenges

1. Patent Expiry and Generic Competition
Late patent expiration results in price erosion and decreased margins. Generics account for a substantial share of prescriptions, intensifying pricing pressures.

2. Market Saturation and Increasing Competition
Other SSRIs (e.g., sertraline, paroxetine) and newer drug classes (SNRIs, atypical antidepressants) provide alternative options, affecting escitalopram’s market share.

3. Regulatory and Off-Label Risks
Regulatory scrutiny over side effect profiles (sexual dysfunction, weight gain) influences prescription patterns. Off-label misuse potential also factors into regulatory considerations.

4. Psychiatrists’ Growing Preference for Personalized Medicine
Tailoring treatments to genetic profiles (pharmacogenomics) may shift prescribing away from broadly prescribed SSRIs, including escitalopram.

---

Financial Trajectory

1. Revenue Trends Post-Patent Expiry
Following patent expiration, pharmaceutical companies' revenues from branded escitalopram declined sharply. According to IQVIA data, Lexapro's U.S. sales declined from approximately USD 2.3 billion in 2012 to under USD 300 million by 2018[4]. Such declines reflect typical patent cliff dynamics in the antidepressant market.

2. Impact of Generic Market Entry
Generic versions significantly cut pricing—by over 70%—which compels brand manufacturers to transition focus toward lower-cost generics and derivative formulations or expand into combination therapies.

3. Regional Market Variability
Developed markets exhibit maturity with declining growth, while emerging markets—such as Asia-Pacific—offer potential for volume-driven growth owing to increasing mental health awareness and improved healthcare infrastructure.

4. Strategic Moves by Manufacturers
Pharmaceutical firms are exploring novel formulations (e.g., extended-release, combination drugs), biosimilars, and digital health integrations to sustain revenue streams related to escitalopram derivatives or brand extensions.

---

Future Outlook

The future trajectory for escitalopram hinges on several factors:

• Patent Strategies and Litigation: Companies might pursue patent extensions or defend against patent challenges to prolong exclusivity.
• Pipeline Development: Innovative SSRIs or multi-mechanism antidepressants could capture market share.
• Digital Health and Pharmacogenomics: Incorporation of personalized medicine practices offers the potential to optimize treatment efficacy, influencing prescribing habits.
• Regulatory & Policy Environment: Reimbursement schemes, pricing controls, and mental health policies will modulate market access and profitability.

While the core generic market remains constrained due to cost competition, niche adaptations and emerging markets represent potential revenue avenues.

---

Implications for Stakeholders

Pharmaceutical Companies
Invest in innovative formulations and expand into emerging markets to offset revenue declines from generics.

Investors
Monitor patent litigations, regulatory changes, and pipeline developments impacting escitalopram-related assets.

Healthcare Providers
Stay informed about evolving guidelines, new pharmacogenomic insights, and alternative therapies to optimize prescribing practices.

Regulators
Ensure safety and efficacy standards are maintained amidst the proliferation of generics to preserve public health.

---

Key Takeaways

• Escitalopram oxalate remains a cornerstone of antidepressant therapy, with a stable but aging market profile.
• Patent expiration and subsequent generic entry have precipitated significant revenue decline.
• Market growth now depends primarily on emerging economies, treatment customization, and pipeline innovations.
• Competitive pressures necessitate strategic adaptations in formulation, marketing, and regional expansion.
• Stakeholders must continuously monitor regulatory, clinical, and market trends to optimize decision-making.

---

FAQs

1. How has patent expiration affected escitalopram's market share?
Patent expiration in 2012 led to widespread generic availability, causing a sharp decline in branded sales and increasing price competition, with generics dominating prescriptions.

2. What are the primary factors influencing escitalopram’s future market growth?
Key factors include emerging market expansion, personalized medicine approaches, patent strategies, and development of novel formulations or combination therapies.

3. How do generics impact the profitability of escitalopram for pharmaceutical companies?
Generics significantly erode profit margins post-pattern expiration, shifting revenue focus toward volume sales and alternative drug innovations.

4. Are there new formulations of escitalopram in development?
Yes, pharmaceutical firms are exploring extended-release formulations and combination therapies to enhance efficacy and differentiate products.

5. What role do regulatory agencies play in the market trajectory of escitalopram?
Regulatory agencies influence through approval processes, safety monitoring, and policy directives impacting drug accessibility, patent protections, and pricing.

---

References

[1] MarketsandMarkets. "Antidepressant Drugs Market by Type and Region." 2022.
[2] WHO. “Depression Fact Sheet,” 2023.
[3] U.S. Patent and Trademark Office. "Lexapro Patent Details," 2011.
[4] IQVIA. “Pharmaceutical Market Data,” 2018.

Note: This article synthesizes current market data and industry trends as of early 2023, assuming typical patent and regulatory timelines.